Treatment of normal platelet-rich plasma with a physiological amount of insulin (100 microunits/ml, optimum concentration) for 3 hours at 23°C stimulated the binding of prostaglandin E1 by more than twofold (3,940±250 sites/108 platelets) compared with the nontreated, control platelet-rich plasma (1,590±265 sites/108 platelets). After platelet-rich plasma from patients with acute ischemic heart disease (n=43), whose platelets showed impaired prostaglandin E,/12 receptor activity (850±100 sites/108 platelets), was incubated with insulin (optimum amounts varied from 100 to 200 microunits/ml), the binding of the prostanoid was restored to normal levels (1,790±140 sites/108 platelets) in 75% of the cases. Twenty-five percent of the patients did not respond to the stimulatory effect of insulin. The (1.0 ,uM) . The treatment of platelet-rich plasma with the hormone decreased the minimum inhibitory concentration of the prostanoid from 34± 14 to 15±9 nM (p<0.001) in the case of normal volunteers and from 49± 15 to 32+11 nM (p =0.002) in the case of "responder" patients. Insulin did not produce any effect on the inhibition of platelet aggregation by the prostaglandin in "nonresponder" patients. In the follow-up study, although the stimulatory effects of insulin on platelets from responder patients were improved to normal levels, the platelets from the nonresponder patients remained persistently unresponsive to the effect of the hormone. (Circulation Research 1991;68:245-254) A ggregation of platelets induced by agonists like thrombin, ADP, l-epinephrine collagen, thromboxane A2, serotonin, and, possibly, platelet-activating factor is believed to be critically important not only in normal blood coagulation but also in the pathogenesis of atherosclerosis and thrombosis (for a review see References 1 and 2). The aggregation of platelets is counterbalanced by several humoral factors, which include prostanoids such as prostacyclin (PG12) and prostaglandin El (PGE1) and proteinase such as blood coagulation factor The prostaglandins inhibit platelet ag-
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Incubation of Normal Platelets With Cardiovascular Medications
To determine the effect of commonly used car- (Figure 3 ). On the other hand, the concentration of the hormone needed to maximize the binding of the radioligand to the platelets from responder AIHD patients varied considerably when compared with that of the normal subjects ( Figure 3 ). Although almost 50% of PRP samples from these patients showed maximal [3H]PGE1 binding at 100 microunits/ml insulin, approximately 30% and 20% of these PRP samples needed 150 and 200 microunits/ml insulin, respectively, for the maximum binding of the radioligand. However, it should be prostaglandin E] (3H-PGE1) to platelets from normal subjects and patients with acute ischemic heart disease. Normalplatelet-rich plasma (-)or platelet-rich plasma from patients with acute ischemic heart disease (-) was incubated with increasing concentrations of insulin as shown. After incubation, platelets were isolated, and the binding of 3H-PGE1 was determnined.
noted that in each case platelets were incubated only with the specific amounts of insulin as indicated in Figure 3 and that the effect of insulin at concentrations between these specific amounts was not tested. As such, the optimum concentrations of insulin could be below the amounts of the hormone as shown. acute ischemic heart disease. Platelet-rich plasma samples were incubated with insulin as described. After incubation, the platelets were isolated and treated with 1.0 pM PGE1 in the presence of 10 mM theophylline. Cyclic AMP formation was then determined. A, normal platelets; B, normal platelets treated with PGE1; C, normalplatelets incubated with insulin (100 microunits/ml) and treated with PGE1; D, platelets firom patients with acute ischemic heart disease; E, platelets from patients with acute ischemic heart disease treated with PGE1; F, platelets from patients with acute ischemic heart disease incubated with insulin and treated with PGEI. platelet-rich plasma incubated with insulin; C, platelet-rich plasma from responder patients with acute ischemic heart disease (control); D, platelet-rich plasma from responder patients with acute ischemic heart disease incubated with insulin; E, platelet-rich plasma from nonresponder patients with acute ischemic heart disease (control); F, platelet-rich plasma from nonresponder patients with acute ischemic heart disease incubated with insulin.
tanoid before and after the incubation of the same PRP from either normal volunteers or AIHD patients with insulin ( Figure 6 ). sponder and nonresponder patients with acute ischemic heart disease during the ischemic episode and in thefollow-up study. Shaded bars indicate the treatment of platelet-rich plasma with insulin. Platelet-rich plasma samples from nine patients with acute ischemic heart disease (six responders and three nonresponders) were incubated with insulin (100 microunitsl ml), and the binding of3H-PGE1 was determined as described.
weeks of recovery ( Figure 7 ). It was found that, in the case of the responders, not only was the impaired binding of PGE1 to platelets (1.16±0.21 fmol/108 platelets) in the acute phase of the attack returned to normal levels (2.34+±0.20 fmol/108 platelets;p<0.001; n=6) during recovery but the diminished response of these platelets to insulin was also normalized (4.35 +0.41 fmol/108 platelets; p<0.001; n=6) in the follow-up study. In contrast, the platelets from nonresponder patients, who failed to respond to the stimulatory effect of insulin during ischemia (1.10+0. 15 The formation of cAMP by PGE1 and the minimum inhibitory concentration of the prostanoid needed to inhibit platelet aggregation improved to normal levels in both insulin-treated and untreated PRP from responder patients when compared with controls (Table 3) at 4-8 weeks of follow-up. In the These results demonstrate that insulin at physiological concentrations (postprandial) regulates platelet function through increased formation of cAMP and by stimulating the binding of PGE1 to these cells. The hormone itself has no effect on the cellular cAMP level. The hyperactivity of platelets and the reduced response to the inhibitory effect of prostaglandin in AIHD have been reported before. [24] [25] [26] [27] [28] We28 and other investigators43,44 have demonstrated that during ischemia the reduced response of platelets to the inhibitory effect of PGE, relates to the impaired PGE1/12 receptor activity of these cells and that the receptor activity returns to normal level during the recovery period. The present data demonstrate that the impaired PGE1 binding of platelets in AIHD could be restored to "normal" levels in 75% of the patients by treating these platelets with physiological amounts of insulin (Figure 2 ).
The platelets from AIHD patients were found to be considerably resistant to the inhibitory effect of PGE1 when compared with normal platelets ( Figure  6 ). Although the stimulatory effect of insulin in the case of platelets from AIHD patients was 50% less than that in the case of normal platelets, the hormone nevertheless decreased the minimum inhibitory concentration of PGE1 in platelets to normal levels. To our knowledge, such normalization of the sensitivity of platelets to the inhibitory effect of prostaglandin in AIHD, albeit in vitro, by a physiological agent has not been achieved before.
Although the mechanism of the increase of PGE1/12 receptor numbers in platelets by insulin is not known, the time course of the stimulatory effect of insulin (Figure 1) , which followed the time course of insulin binding to these cells,34,45 suggests a dependence of the process on the insulin receptor interaction. It has been shown above that, unlike the normal platelets, the platelets from the AIHD patients showed considerable variation in the optimum dose of insulin for maximizing the binding of [3HJPGE1 to these platelets (Figure 3 ). Since this variation of the optimum concentration of the hormone could not be corrected by washing these platelets nor did it appear to arise from interference caused by the presence of cardiac medications in the samples of PRP (Table 1) , it is possible that the above variation was related to the insulin receptor status of the platelets.
On the basis of the response of their platelets to the stimulatory effect of insulin, AIHD patients were subgrouped as responders or nonresponders ( Figure  2 ). The effect of insulin on the platelets from the nonresponder AIHD patients was tested by using up to 200 microunits/ml of the hormone. It is not known whether these nonresponder platelets will respond in the presence of higher amounts of insulin. However, although the impairment of PGE1/12 receptor activity in these platelets was transient, the lack of response of platelets from the nonresponder AIHD patients was longer lasting. Even after 4-8 weeks of recovery, when the [3H]PGE1 binding of platelets in the responder patients returned to near normal level, the platelets of nonresponders remained persistently unresponsive to the effect of insulin (Figure 7 ). Although it is possible that the nonresponder platelets might eventually respond after a longer period of recovery, similar lack of response to the stimulatory effect of insulin hormone is also known to occur in the case of platelets from diabetes mellitus (type II) patients with impaired insulin binding to these cells.46 It remains to be determined whether the lack of response of platelets from these AIHD patients was due to disorders in the insulin receptor binding or was the consequence of derangement in postreceptor interaction phenomena. The lack of the hormonal stimulation might, however, predispose the nonresponder AIHD patients to a higher risk of developing recurrent cardiac ischemic conditions, particularly in the case of reduced availability of PGE1 or PGI2 in the circulation. The hyperactivity of platelets in AIHD patients has been shown to be a significant factor in the pathogenesis of recurrent cardiac ischemia. We have found the platelets from AIHD patients (n=54) who had not taken aspirin required significantly lower amounts of ADP for aggregation (2. function by infusion of PGI2 in this condition has been proved to be disappointing,24'27 partly due to the loss of sensitivity of platelets to the inhibitory effect of the prostaglandins.22,3334 Although the impaired PGE1/12 receptors of platelets in AIHD patients would play a critical role in the development of coronary artery thrombosis, endothelial injury and dynamic vasoconstriction would also be equally important in the process. [16] [17] [18] [19] [20] [21] [22] Restoration of the prostanoid receptor activity of these platelets by insulin to a normal level might inhibit, at least partly, thrombus formation; this suggests a new approach to the reduction of hyperactivity in platelets in AIHD. However, the extension of the in vitro stimulatory effect of insulin on platelet PGE1/I2 receptors to in vivo conditions must be made with caution.
